Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 45Neoplasms 26Colorectal Neoplasms 24Neoplasm Metastasis 22Recurrence 21Ovarian Neoplasms 21Pancreatic Neoplasms 20Breast Neoplasms 19Squamous Cell Carcinoma of Head and Neck 17Melanoma 16Glioblastoma 15Prostatic Neoplasms 14Lymphoma, Large B-Cell, Diffuse 13Endometrial Neoplasms 13Precursor Cell Lymphoblastic Leukemia-Lymphoma 12Multiple Myeloma 12Lymphoma, Non-Hodgkin 12Triple Negative Breast Neoplasms 11Lung Neoplasms 11Glioma 10Colonic Neoplasms 10Carcinoma, Renal Cell 10Stomach Neoplasms 9Rectal Neoplasms 9Gastrointestinal Neoplasms 9Lymphoma, Follicular 8Lymphoma 8Leukemia, Myeloid, Acute 8Head and Neck Neoplasms 8Brain Neoplasms 8

Interventions

resiniferatoxin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Pain, Intractable × 30 days × Clear all
NCT02522611 2026-06-01

Periganglionic Resiniferatoxin for the Treatment of Intractable Pain Due to Cancer-induced Bone Pain

National Institutes of Health Clinical Center (CC)

Phase 1/2 Not yet recruiting
30 enrolled

Cancer Pain, Pain, Intractable

Data powered by HemOnc (CC BY 4.0) Colophon âš¡